CORC

在结果中检索

CORC

浏览/检索结果: 共57条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety 期刊论文
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2022, 页码: 9
作者:  Zhang, Jingfang;  Li, Wenzhe;  Qi, Yafei;  Wang, Guorong;  Li, Lele
收藏  |  浏览/下载：14/0  |  提交时间：2023/02/22
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Jing;  Lou, Hanmei;  Cai, Hong-Bing;  Huang, Xin;  Li, Guiling
收藏  |  浏览/下载：17/0  |  提交时间：2022/12/23
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin
收藏  |  浏览/下载：22/0  |  提交时间：2022/05/16
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial 期刊论文
LANCET ONCOLOGY, 2022, 卷号: 23
作者:  Zhou, Qing;  Chen, Ming;  Jiang, Ou;  Pan, Yi;  Hu, Desheng
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/21
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao
收藏  |  浏览/下载：43/0  |  提交时间：2022/02/14
Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice 期刊论文
JOURNAL OF INFLAMMATION RESEARCH, 2022, 卷号: 15, 页码: 545-556
作者:  Geng, Yichao;  Su, Shengfa;  Cao, Li;  Yang, Ting;  Ouyang, Weiwei
收藏  |  浏览/下载：26/0  |  提交时间：2022/04/11
A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer 期刊论文
FRONTIERS IN IMMUNOLOGY, 2021, 卷号: 12
作者:  Peng, Jie;  Zou, Dan;  Han, Lijie;  Yin, Zuomin;  Hu, Xiao
收藏  |  浏览/下载：23/0  |  提交时间：2022/02/14
BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer 期刊论文
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6, 期号: 1, 页码: 14
作者:  Feng, Mei;  Wu, Zhongen;  Zhou, Yan;  Wei, Zhuang;  Tian, Enming
收藏  |  浏览/下载：29/0  |  提交时间：2021/11/04
Engineering Nanoscale Artificial Antigen-Presenting Cells by Metabolic Dendritic Cell Labeling to Potentiate Cancer Immunotherapy 期刊论文
NANO LETTERS, 2021, 卷号: 21, 期号: 5, 页码: 2094-2103
作者:  Xiao, Ping;  Wang, Jue;  Zhao, Zitong;  Liu, Xiaochen;  Sun, Xiangshi
收藏  |  浏览/下载：26/0  |  提交时间：2021/05/24
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden 期刊论文
FRONTIERS IN ONCOLOGY, 2021, 卷号: 10
作者:  Wang, Rong;  Yang, Yuchen;  Ye, Wei-Wu;  Xiang, Jianxing;  Chen, Songan
收藏  |  浏览/下载：44/0  |  提交时间：2021/04/26

©版权所有 ©2017 CSpace - Powered by CSpace